Effects of inhaled tiotropium on left ventricular diastolic function in chronic obstructive pulmonary disease patients after pulmonary resection.
OBJECTIVE
The objective of the present study was to evaluate the effects of inhaled tiotropium on pulmonary function and left ventricular diastolic function in chronic obstructive pulmonary disease patients ≥ 1 year after pulmonary resection for lung cancer.


METHODS
This prospective single-arm analysis involved 21 chronic obstructive pulmonary disease patients who underwent pulmonary resection for lung cancer at least one year earlier. Blood pressures, heart rate, spirometry, transthoracic echocardiography including tissue Doppler imaging, and quality of life were evaluated prior to and after 3 months of inhaled tiotropium treatment. B-type natriuretic peptide, white blood cell counts, and C-reactive protein levels before and after inhaled tiotropium treatment were also examined.


RESULTS
There were no significant differences between before and after treatment in forced vital capacity and left ventricular ejection fraction. Forced expiratory volume in 1 second and early transmitral velocity/tissue Doppler mitral annular early diastolic velocity values improved from 1.60 ± 0.5 L and 8.97 ± 1.6, respectively, before treatment, to 1.84 ± 0.5 L and 7.59 ± 1.4, respectively, 3 months after treatment (P <0.001).


CONCLUSIONS
Treatment with inhaled tiotropium may be effective in improving not only pulmonary function but also left ventricular diastolic function of patients with chronic obstructive pulmonary disease in the chronic phase after pulmonary resection.
Departments of General Thoracic Surgery, National Hospital Organization Toneyama Hospital, Toyonaka, Osaka, Japan. nojirit@thoracic.med.osaka-u.ac.jp
Takashi
T
Nojiri
Kazuhiro
K
Yamamoto
Hajime
H
Maeda
Yukiyasu
Y
Takeuchi
Yasunobu
Y
Funakoshi
Ryoji
R
Maekura
Meinoshin
M
Okumura
D000280:Administration, Inhalation; D000368:Aged; D015415:Biomarkers / Q000097:blood; D001993:Bronchodilator Agents / Q000008:administration & dosage*; D003971:Diastole / Q000187:drug effects*; D015150:Echocardiography, Doppler; D005260:Female; D005541:Forced Expiratory Volume / Q000187:drug effects; D006801:Humans; D007564:Japan; D008168:Lung / Q000187:drug effects* / Q000503:physiopathology / Q000601:surgery*; D008175:Lung Neoplasms / Q000150:complications / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011013:Pneumonectomy; D011446:Prospective Studies; D029424:Pulmonary Disease, Chronic Obstructive / Q000097:blood / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D020127:Recovery of Function; D012602:Scopolamine Derivatives / Q000008:administration & dosage*; D013147:Spirometry; D013318:Stroke Volume / Q000187:drug effects; D013997:Time Factors; D000069447:Tiotropium Bromide; D016896:Treatment Outcome; D016277:Ventricular Function, Left / Q000187:drug effects*; D014797:Vital Capacity / Q000187:drug effects
D015415:Biomarkers; D001993:Bronchodilator Agents; D012602:Scopolamine Derivatives; D000069447:Tiotropium Bromide